Navigation Links
Shire plc: Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
Date:7/18/2011

colitis and for the maintenance of remission of ulcerative colitis. Lialda is available as a delayed-release tablet containing 1.2 g mesalamine. For the induction of remission in patients with active, mild to moderate ulcerative colitis, the recommended dosage is two or four 1.2 g tablets taken once daily with a meal. The recommended dosage for the maintenance of remission of ulcerative colitis is two 1.2 g tablets taken once daily with a meal.


About Ulcerative Colitis


Ulcerative colitis is a type of inflammatory disease. It only affects the colon, producing chronic inflammation and sometimes sores or ulcers along the inside lining of the colon. It is characterized by diarrhea, which is generally bloody, and often painful cramping in the abdomen. Currently, there is no cure available with medical treatment, and the cause of the disease is unknown.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFEHARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not hi
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Shire plc : Second Quarter 2011 Results Date Notification - July 28, 2011
2. Shire Files Lawsuits Against Sandoz and Amneal for Infringement of VYVANSE® (lisdexamfetamine dimesylate) Patents
3. United Lincolnshire Hospitals NHS Trust Selects Jayex QI Interactive Patient Survey and Information Management Kiosk
4. Shire Completes Acquisition of Advanced BioHealing, Inc.
5. European Authorities Approve New Manufacturing Facility for Shires REPLAGAL® (agalsidase alfa)
6. Prasco Announces Agreement with Shire for Future Exclusive Distribution and Supply of Authorized Generic for PENTASA®
7. Shire Recognized by ISPE Facility of the Year Awards Program
8. Reportlinker Adds Shire plc: PharmaVitae Profile
9. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
10. Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010
11. Atrium Recognized by New Hampshire Bio/Medical Council
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... 2013  PTC Therapeutics, Inc., today announced that it ... the U.S. Securities and Exchange Commission ("SEC") relating to ... The number of shares to be offered and the ... (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... book-running managers for the offering. Cowen and Company is ...
(Date:5/16/2013)... and SYDNEY , May 16, ... - ASX: HIN), a leading innovator of less invasive, miniaturized ... heart failure, today announced that CEO Doug Godshall ... Global Healthcare Conference at 11:00 a.m. EDT on Monday, May ... at the Sheraton New York Hotel. A live ...
(Date:5/16/2013)... , May 16, 2013 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for the treatment ... Richard King , President and CEO, will present a ... Sheraton New York Hotel in New York ... 2013 at 9:30 a.m. ET/6:30 a.m. PT. The ...
Breaking Medicine Technology:PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 3
(Date:5/18/2013)... Children who swallow high-powered magnets often need surgery and ... a new study. The researchers, from the Louisiana ... more than 79 percent of children who swallowed very ... procedure, in which a tube containing a camera is ... these cases can be treated through observation or by ...
(Date:5/18/2013)... 18, 2013) The use of a smartphone ... according to new research presented today at Digestive ... days in advance of the procedure, includes dietary ... be taken at strict intervals. The better the ... see cancer and precancerous polyps in the colon. ...
(Date:5/18/2013)... In a May 14, 2013 article entitled ... Discovering Cancer Gene,” Fox News reported the movie star ... she carried a gene that doctors estimated gave her ... 50 percent risk of ovarian cancer (go to: goo.gl/5JHBP). ... 2013 with a blog post entitled “A Patient’s Journey: ...
(Date:5/18/2013)... 18, 2013 Today, Zane Benefits, ... agents’ role in Marketplaces . Zane Benefits, which ... sponsored health benefits, is the leader in health ... health reimbursement arrangements . , According to Zane ... Services (HHS) recently released a much-anticipated statement and ...
(Date:5/18/2013)... Serena Gordon HealthDay Reporter , , FRIDAY, May 17 ... students sometimes binge drink, but new research shows that college ... on a weekly basis than are college men. ... alcohol that,s considered safe on a weekly basis is much ... for women versus 14 for men. But, there,s good reason ...
Breaking Medicine News(10 mins):Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:New smartphone application improves colonoscopy preparation 2Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3
... OxyContin in late 1995 and the drug was put ... and 2000, prescriptions for the drug have increased by ... powerful heroin-like high by crushing the pill and injecting, ... OxyContin, the nation's best selling prescription painkiller, began in ...
... eye’s retina is well on its way to offering ... as retinitis pigmentosa and age-related degeneration of the eye ... implant works for eye diseases in which healthy retinal ... eye’s photoreceptors.// These receptors convert images into electric impulses. Researchers ...
... nose can be unpleasant, but doctors say that discomfort ... decongestants if you have high blood pressure. Though they ... contain decongestants such as pseudoephedrine and phenylephrine, which doctors ... products containing such ingredients are required to list such ...
... Scientific study suggests that the much famed tanning salons, ... chances of a number of more common skin cancers. ... National Cancer Institute claims to have found a relationship ... like basal cell carcinoma, squamous cell carcinoma and melanoma. ...
... fertility found that women who experienced pleasurable sex retained more ... The best way to get pregnant is to have a ... Cathy, from the School of Psychology at Ohio University, studied ... were asked to go to a clinic within a few ...
... Researchers state that weekend alcohol flings and the stress of ... increased rate of heart attack. A 7 year study carried ... die from heart attacks on a Monday than any other ... the nexus between exorbitant drinking and coronary heart disease.//They suggested ...
Cached Medicine News:
... well as humidification, try Flo-Mist™., ,Flo-Mist™, ... continuous medication nebulizer (CMN), engineered to deliver ... ml reservoir and jet flow design allow ... medication delivery at 25 ml/hr. Particles are ...
Nebulizer Custom Kit...
... Innovators in Anesthesia and Respiratory Products, ... quality medical devices for Anesthesia and Respiratory ... manufacture products that enhance the clinician's ability ... close attention to the bottom line. , ...
... nebulizer achieves optimum lung penetration for maximum ... is 1.04-1.10 µ at 6-8 LPM. Latex-free ... ,As the world leader in airway ... assurance of proven technology by offering top ...
Medicine Products: